8-Cyclohexyl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester → 8-Cyclohexyl-2-{4-[2-(morpholine-4-sulfonyl)-ethyl]-phenylamino}-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester
Reaction equation
[N:1]1([S:7]([CH2:10][CH2:11][C:12]2[CH:17]=[CH:16][C:15]([NH2:18])=[CH:14][CH:13]=2)(=[O:9])=[O:8])[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[CH2:19]([O:21][C:22]([C:24]1[C:25](=[O:44])[C:26]2[CH:31]=[N:30][C:29](S(C)(=O)=O)=[N:28][C:27]=2[N:36]([CH:38]2[CH2:43][CH2:42][CH2:41][CH2:40][CH2:39]2)[CH:37]=1)=[O:23])[CH3:20]>>[CH2:19]([O:21][C:22]([C:24]1[C:25](=[O:44])[C:26]2[CH:31]=[N:30][C:29]([NH:18][C:15]3[CH:16]=[CH:17][C:12]([CH2:11][CH2:10][S:7]([N:1]4[CH2:2][CH2:3][O:4][CH2:5][CH2:6]4)(=[O:9])=[O:8])=[CH:13][CH:14]=3)=[N:28][C:27]=2[N:36]([CH:38]2[CH2:43][CH2:42][CH2:41][CH2:40][CH2:39]2)[CH:37]=1)=[O:23])[CH3:20]Participants
3
Reactant 2
Product 1
Procedure
Using the procedure outlined in Example 1 (g) the title compound was prepared from 4-[2-(morpholine-4-sulfonyl)-ethyl]-phenylamine (from Example 35(A), 75 mg, 0.28 mmol) and 8-cyclohexyl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 17(e), 100 mg, 0.26 mmol). The title compound was obtained as a yellow solid (57 mg, 38%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.26 (s, 1H), 8.46 (s, 1H), 7.65 (br, 1H), 7.55 (d, J=8.4 Hz, 2H), 7.19 (d, J=8.4 Hz, 2H), 5.04 (m, 1H), 4.32 (q, J=7.1 Hz, 2H), 3.68 (m, 4H), 3.22 (m, 4H), 3.10 (m, 4H), 2.00 (m, 4H), 1.80 (m, 1H), 1.62 (m, 2H), 1.48 (m, 2H), 1.34 (t, J=7.1 Hz, 3H), 1.31(m, 1H).
Sources & evidence
- ORD record
- ord-ff7bebe76d1a46748b9a4816a17df72e
- Source dataset
- uspto-grants-2010_01
- Patent number
- US07642270B2
Reaction notes
Loading…